The company said this could open the door for ... will face competition after its patent expires in 2028. A Merck logo is shown on a scientist's lab coat. The Food and Drug Administration, on ...

Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA ...

The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), with a ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Merck & Company (MRK – Research ...

Leaders at Merck & Co. Inc. are facing a new derivative shareholder lawsuit over allegations that they made misleading ...

According to Benzinga Pro, Merck & Co's peer group average for short interest as a percentage of float is 4.19%, which means ...

In 2010, Merck bought back the plant after selling it to a contract manufacturer in 2008. Prior to the plant sale, the company had operated the site for 58 years. Merck has an overall Pennsylvania ...

In an emailed statement, a Merck spokesperson said that the company is “extremely pleased” with the court’s decision and stands by the safety of its vaccine. “The evidence that Gardasil ...

The company said this could open the door for other cancers treated by Keytruda and potentially give Merck a new product at a time when the drug, which brought in nearly $30 billion in revenue in ...